Crossmark

Engineered Nanoscale Lipid-Based Formulation as Potential Enhancer of Gefitinib Lymphatic Delivery: Cytotoxicity and Apoptotic Studies Against the A549 Cell Line

Crossref DOI link: https://doi.org/10.1208/s12249-022-02332-7

Published Online: 2022-07-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sherif, Abdelrahman Y.

Harisa, Gamaleldin I.

Alanazi, Fars K.

Nasr, Fahd A.

Alqahtani, Ali S.
License Information

Text and Data Mining valid from 2022-07-01

Version of Record valid from 2022-07-01
More Information

Article History

Received: 23 April 2022

Accepted: 14 June 2022

First Online: 1 July 2022

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below